Indian Journal of Bioinformatics and Biotechnology

Open Access Open Access  Restricted Access Subscription Access

Molecular Docking Analysis of Sorbitol Dehydrogenase Using Ligandfit Algorithm


Affiliations
1 Department of Biotechnology, Faculty of Science and Humanities, SRM University, Kattankulathur – 603 203, Tamil Nadu, India
2 Department of Biotechnology, CRD, PRIST University, Thanjavur – 613 403,Tamil Nadu, India
3 Department of Bioinformatics,School of Bioengineering, SRM University, Kattankulathur – 603 203, Tamil Nadu, India
 

Diabetic retinopathy is a major cause of visual impairment worldwide. The polyol pathway is a two step metabolic process in which the enzyme aldose reductase reduces glucose to sorbitol using NADPH as a cofactor; Sorbitol is then metabolized to fructose by sorbitol dehydrogenase (SORD) that uses NAD+ as cofactor. Human sorbitol dehydrogenase is a tetramer of identical, catalytically active sububits. Recent evidence suggests that the inhibition of both sorbitol and fructose is required to achieve beneficial effects in diabetic retinopathy. In our present study the molecular docking analysis of sorbitol dehydrogenase was carried out using Accelyr's Discovery studio software (uses LIGANDFIT algorithm). The binding affinity of several ligands to the target protein was calculated based on the dock scores obtained. It was found that out of 210 compounds 21 ligands docked to SORD whereas 17 ligands failed to dock and 59 ligands were found to be without hits. Among the 21 ligands, Dithiodialanine had greater binding affinity with the receptor thereby it can be recommended as a drug for the treatment of diabetic retinopathy.

Keywords

Diabetic Retinopathy, Sorbitol Dehydrogenase, Molecular Docking, LIGANDFIT
User
Notifications

  • Ferris FL (1993) Diabetic Retinopathy Diabetes Care, 16: 322-5.

  • Klein R, Klein BE, Moss SE, Cruickshanks KJ (1994) Relationship of hyperglycemia to the long term incidence and progression of diabetic retinopathy, Arch. Intern. Med.,154: 2169-78.

  • Rosenblatt BJ, Benson WE, Diabetic Retinopathy In: Yanoff M, Duken JS editors Opthalmology 2nd edition St.Louis: Mosby 877-86.

  • Resnikoff S, Pascolini D, Etya’ale D, KocurI, Pararajasegaram R, Pokharel GP, Mariotti SP (2004) Global data on visual impairment, Bull World Health Organ., 82: 844-51.

  • Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications, Nature, 414: 813-20.

  • Szwergold BS, Kappler F, Brown. TR (1990) Identification of fructose 3-phosphate in the lens of diabetic rats Science, Vol 247 no: 4941, 451-454.

  • Gonzalex RG, Miglior S, Von Saltza L, Buckley L Neuringer J and Cheng HM (1988) 31P NMR studies of the diabetic lens Magnetic Resonance in Medicine Vol 6, No.4, 435-444.

  • Demaine A, Cross D, Millward A. (2000) Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus, Invest Ophthalmol Vis Sci., 41:4064-8.

  • Wang Y, Ng MC, Lee SC, So WY, Tong PC, Cockram CS, Critchley JA, Chan JC. (2003) Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes, Diabetes Care, 26:2410-5.

  • Joanna M. Tarr, Kirti Kaul, Mohit Chopra, Eva M. Kohner, and Rakesh Chibber (2013) Pathophysiology of Diabetic Retinopathy ISRN Ophthalmology Volume, 13 pages.

  • I. G. Obrosova, A. G. Minchenko, R. Vasupuram et al., (2003) Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats”, Diabetes, vol. 52, no. 3, pp. 864–871.

  • P. J. Oates and B. L. Mylari, (1999) “Aldose reductase inhibitors: therapeutic implications for diabetic complications,” Expert Opinion on Investigational Drugs, vol. 8, no. 12, pp. 2095–2119.

  • W. Sun, P. J. Oates, J. B. Coutcher, C. Gerhardinger, and M. Lorenzi, (2006) “A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy,” Diabetes, vol. 55, no. 10, pp. 2757–2762.

  • P. J. Oates, (2008) “Aldose reductase, still a compelling target for diabetic neuropathy,” Current Drug Targets, vol. 9, no. 1, pp. 14–36.

  • S. Amano, S. I. Yamagishi, Y. Koda et al., (2003) “Polymorphisms of sorbitol dehydrogenase (SDH) gene and susceptibility to diabetic retinopathy”, Medical Hypotheses, vol. 60, no. 4, pp. 550–551.

  • Jeffrey, J., Cummins, L., Carlquist, M., and Jornvall, H. (1981) Properties of sorbitol dehydrogenase and characterization of a reactive, Cysteine residue reveal unexpected similarities to alcohol dehydrogenases, Eur. J. Biochem. 120, 229–234.

  • Banfield, M.J., Salvucci, M.E., Baker, E.N., and Smith, C.A. (2001) Crystal structure of the NADP(H)-dependent ketose reductase from Bemisia argentifolii at 2.3 A°resolution. J. Mol. Biol. 306, 239–250.

  • Johansson, K., El-Ahmad, M., Kaiser, C., Jornvall, H., Eklund, H., and Hoog, J.-O. (2001) Crystal structure of sorbitol dehydrogenase, Chem. Biol. Interact., 130, 351–358.

  • Ruzheinikov, S.N., Burke, J., Sedelnikova, S., Baker, P.J., Taylor, R., Bullough, P.A., Muir, N.M., Gore, M.G., and Rice, D.W. (2001) Glycerol dehydrogenase: structure, specificity, and mechanism of a family III polyol dehydrogenase, Structure 9, 789–802.

  • Jeffrey, J., Chesters, J.,Mills, C., Sadler, P.J., and Jornvall, H. (1984) Sorbitol dehydrogenase is a zinc enzyme, EMBO J. 3, 357–360.

  • Maret, W. (1996) Human sorbitol dehydrogenase—a secondary alI., cohol dehydrogenase with distinct pathophysiological roles, pHA dependent kinetic studies, Adv. Exp. Med. Biol., 414, 383–393.

  • Geraniol and Limonene Interaction with 3-hydroxy-3- methylglutaryl- CoA HMG-CoA) Reductase for their Role as Cancer Chemo-preventive Agents, Madhumita Pattanayak, P K Seth, Suchi Smita, Shailendra K Gupta Proteomics Bioinform 2: 466-474.

  • E. M. Krovat, T. Steindl & T. Langer, (2002) “Recent Advances in Docking and Scoring”, Comput.Aided Mol. Des.

  • Vivek Srivastava, et.al., (2008) “Molecular docking studies on DMDP derivatives as human DHFR Inhibitors”, Biomedical Informatics.


Abstract Views: 547

PDF Views: 394




  • Molecular Docking Analysis of Sorbitol Dehydrogenase Using Ligandfit Algorithm

Abstract Views: 547  |  PDF Views: 394

Authors

V. G. Vidhya
Department of Biotechnology, Faculty of Science and Humanities, SRM University, Kattankulathur – 603 203, Tamil Nadu, India
Anusha Bhaskar
Department of Biotechnology, CRD, PRIST University, Thanjavur – 613 403,Tamil Nadu, India
S. Vijayasri
Department of Bioinformatics,School of Bioengineering, SRM University, Kattankulathur – 603 203, Tamil Nadu, India

Abstract


Diabetic retinopathy is a major cause of visual impairment worldwide. The polyol pathway is a two step metabolic process in which the enzyme aldose reductase reduces glucose to sorbitol using NADPH as a cofactor; Sorbitol is then metabolized to fructose by sorbitol dehydrogenase (SORD) that uses NAD+ as cofactor. Human sorbitol dehydrogenase is a tetramer of identical, catalytically active sububits. Recent evidence suggests that the inhibition of both sorbitol and fructose is required to achieve beneficial effects in diabetic retinopathy. In our present study the molecular docking analysis of sorbitol dehydrogenase was carried out using Accelyr's Discovery studio software (uses LIGANDFIT algorithm). The binding affinity of several ligands to the target protein was calculated based on the dock scores obtained. It was found that out of 210 compounds 21 ligands docked to SORD whereas 17 ligands failed to dock and 59 ligands were found to be without hits. Among the 21 ligands, Dithiodialanine had greater binding affinity with the receptor thereby it can be recommended as a drug for the treatment of diabetic retinopathy.

Keywords


Diabetic Retinopathy, Sorbitol Dehydrogenase, Molecular Docking, LIGANDFIT

References